ReviewFuture oncology (London, England)2025
Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET.
Review in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Heptanuclear iron complex as a potential contrast agent for MRI.Magnetic resonance letters · 2026Article
- Contrast Agents for Enhanced Bioimaging: A Comprehensive Review.Chembiochem : a European journal of chemical biology · 2026Review
- Iron-Based Nanoparticles as Delivery Tools.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Editorial: Metal-based nanomaterials for tumor diagnosis and therapy.Frontiers in chemistry · 2025Article
- Challenges and Future Prospects of Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in Nanomedicine: A Focus on Toxicity, Imaging, and Theranostics.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomedicine has emerged as a transformative field in medical diagnostics, particularly in cancer detection. Superparamagnetic iron oxide nanoparticles (SPIONs) and ultrasmall superparamagnetic iron oxide nanoparticles (USPIONs) have garnered significant attention due to their remarkable properties, making them suitable for use in molecular imaging. These nanoparticles can serve as effective contrast agents for magnetic resonance imaging (MRI) and can also be radiolabeled with various radioisotopes for use in nuclear medicine modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Recent advancements in multimodal imaging systems, such as PET/MRI and SPECT/MRI, have demonstrated the potential of these nanoparticles to combine the strengths of different imaging techniques, allowing for more accurate cancer detection at early stages. MRI provides high spatial and temporal resolution but lacks sensitivity, while PET and SPECT offer high sensitivity with lower resolution. The integration of these modalities allows for enhanced imaging of cancerous tissues. This review discusses the application of radiolabeled SPIONs and USPIONs in dual-modality imaging systems, highlighting their advantages and limitations as contrast agents. The continued development of targeted nanoprobes and the exploration of new multimodal imaging systems offer promising avenues for improving early cancer diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.